PALB2 and breast carcinoma: In their study 60% (12/20) of PALB2 and 58% (7/12) of ATM/CHEK2 carriers with breast cancer underwent RRM compared to 57% (4/7) and 29% (2/7) of those without breast cancer, respectively (Cragun, 2020).